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Abstract
Angiogenesis and the development of a vascular network is required for tumor progression, and 
involves release of angiogenic factors, including vascular endothelial growth factor (VEGF), from 
both malignant and stromal cell types1. Infiltration by cells of the myeloid lineage is a hallmark of 
many tumors, and in many cases the macrophages in these infiltrates express VEGF2. Here we 
show that deletion of inflammatory cell-derived VEGF attenuates the formation of a typical high-
density vessel network, thus blocking the angiogenic switch in solid tumors. Vasculature in tumors 
lacking myeloid cell-derived VEGF was less tortuous, with increased pericyte coverage and 
decreased vessel length, indicating vascular normalization. In addition, loss of myeloid-derived 
VEGF decreases VEGFR2 phosphorylation in tumors, even though overall VEGF levels in the 
tumors are unaffected. However, myeloid deletion of VEGF resulted in an accelerated tumor 
progression in multiple subcutaneous isograft models and an autochthonous transgenic model of 
mammary tumorigenesis, with less overall tumor cell death and decreased tumor hypoxia. 
Furthermore, loss of myeloid cell VEGF increased tumor susceptibility to chemotherapeutic 
cytotoxicity. This demonstrates that myeloid-derived VEGF is essential for tumorigenic alteration 
of vasculature and signaling to VEGFR2, and that these changes act to retard, not promote, tumor 
progression.
To test the role of myeloid cell-derived VEGF in tumor progression, we created an in vivo, 
cell lineage-specific targeted deletion of VEGF via crosses of the loxP-flanked VEGF allele3 
to the lysozyme M promoter-driven cre recombinase4; this expression is specific to cells of 
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the myeloid lineage, including neutrophils and macrophages, but not dendritic cells 
(LysMCre/VEGF+f/+f)4. This results in VEGF gene excision in approximately 75% of 
isolated neutrophils, peritoneal macrophages5, and tumor associated macrophages 
(Supplementary Figure 1a).
To determine the function of myeloid cell-derived VEGF in an autochthonous mouse model 
of breast cancer, we then crossed these alleles to the MMTV-PyMT transgenic mouse 
strain6. To mitigate the influence of strain variation, individual transgenic alleles were 
backcrossed to >99% C57Bl/6J strain background (as assayed by SNP analysis).
As both genotypes carry the PyMT transgene, mice with a myeloid cell-specific deletion of 
VEGF-A (MMTV-PyMT/LysMCre+/VEGF+f/+f) will be termed mutant mice (Mut), 
whereas cre-negative mice (MMTV-PyMT/LysMCre-/VEGF+f/+f) will be termed wild-type 
(WT) (Supplementary Figure 1b).
To determine the time point of tumor onset, mammary glands of virgin WT and Mutant 
mice were palpated once a week. The first palpable tumor occurred at an average age of 11 
weeks (Supplementary Figure 1d). Tumors were removed at two different time points, and 
total tumor burden from each mouse was evaluated. At 16 weeks, tumors from wild type and 
mutant animals showed no difference in total tumor mass (Supplemental Figure 1e). 
However, at 20 weeks, mutant mice had a significantly higher tumor burden than their wild 
type littermates (Figure 1a). At this point, tumors from wild type animals had increased their 
total mass by almost 400% relative to the 16 week time point; tumors from mutants showed 
an increase in tumor mass of almost 600% compared to the 16 week time point.
A quantitative analysis of proliferating cells showed that the number of PCNA-positive cells 
increased with progression to malignancy (Supplementary Figure 1h) and that loss of 
myeloid cell-derived VEGF increased proliferation rates significantly in the early stages of 
malignant transformation (Supplementary Figure 1h). Detection of Polyoma middle T 
antigen and PCNA immunohistologically demonstrated that the proliferating cell types were 
primarily mammary epithelium (Supplementary Figure 1f).
In order to address whether the level of malignant progression mirrored tumor mass results, 
we histologically assessed tumor progression for each time point based on representative 
sections from each mammary gland using the criteria described in Lin, et al.7 in a blinded 
fashion. As depicted in Figure 1b, at the time point of 16 weeks, the majority of mammary 
gland tissues from both wild type and mutant animals are still at premalignant stages (96.2% 
and 89.5%, by area, respectively). After 20 weeks, the majority of tissues in mutant mice 
had progressed to malignant stages [EC (38.0%) and LC (52.5%)]. In wild type animals, 
mammary tissues were primarily at premalignant (30.9%) and early carcinoma (50.2%) 
stages; a minority of the tissue (18.9%) possessed late carcinomatous lesions (Figure 1b). 
These results indicated, surprisingly, that tumors develop at a more rapid pace in the absence 
of macrophage-derived VEGF.
Quantitative analysis of vessel density was then carried out (Figures 1c-1e, Supplementary 
Figure 1g). In wild-type mice, pre-malignant lesions have a low vascular density, which is 
reduced in myeloid VEGF null mutant mice (Figure 1c). Increased vascular density was 
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found in tumors that had progressed to the malignant, early carcinoma (EC) stage, consistent 
with occurrence of an “angiogenic switch” during the transition to malignancy (Figure 1c). 
In late carcinoma stage tumors formed by multiple solid nodular areas, the overall vascular 
density was similar to that seen in the early carcinoma stage in wild type animals. However, 
in mutant mice, the malignancy-associated increased vascularization seen in wild type 
animals does not occur (Figure 1c). The length and the tortuosity of tumor blood vessels was 
also affected by the mutation: as depicted in Figure 1d, the average vessel length in tumors 
in wild type mice increased as tumors progressed to malignancy, indicating that vessel 
elongation plays a key role in the formation of a tumor vessel network in this model. Along 
with this increase, blood vessel tortuosity more than doubled in malignant lesions in wild 
type mice (Figure 1e). In tumors within mutant mice, there was no increase in vessel length 
prior to the late carcinoma stage (Figure 1d), and vessel tortuosity never changed in the 
mutants (Figure 1e).
Gene-expression analysis of lysates of mammary tumors from mice at the endpoint age of 
20 weeks did not reveal any increase in expression of hypoxia markers, such as the PGK 
gene (Supplementary Figure 1i). However, this analysis of tumors did demonstrate that there 
was higher expression of VEGF mRNA in tumors from mutant animals (Supplementary 
Figure 1j). This was not mirrored by changes in VEGF protein, however, which did not vary 
in tumor lysates from wild type and mutant animals (Figure 1f).
We next wished to determine whether signaling to the tumor endothelium was affected by 
the loss of myeloid-derived VEGF. VEGFR2 is a primary endothelial cell-specific receptor 
tyrosine kinase that participates in VEGF signalling. By immunoprecipitating VEGFR2 
from tumor lysates and probing with anti-phosphotyrosine followed by anti-VEGFR2 
antibody via western blot, we were able to quantify activated and total VEGFR2 from wild 
type and mutant tumors. As shown in Figure 1g, loss of myeloid-derived VEGF causes an 
approximately 50% reduction in the ratio of phosphorylated VEGFR2 relative to total 
VEGFR2, when compared to wild type tumor lysates. Reduced VEGFR2 phosphorylation 
suggests that myeloid cell-derived VEGF plays a unique role in tumor vascularization that 
cannot be compensated for by VEGF from other sources within the tumor.
To analyze these effects in fully transformed cells, we next carried out experiments with 
subcutaneous isografts of Lewis Lung Carcinoma (LLC) cells. LLC tumors in myeloid 
VEGF null mutant mice had significantly greater tumor volumes at day 12 (Figure 2a), with 
no genotype-specific differences in tumor infiltration (Supplementary Figure 2). Flow 
cytometric analysis demonstrated that macrophages were the predominant myeloid infiltrate, 
and that levels of infiltrating macrophages and less abundant neutrophils were similar across 
genotypes (Supplementary figure 2).
A significant reduction in vascular density and vessel tortuosity was again observed in 
mutant mice (Figures 2b and 2c). An analysis of VEGF protein and mRNA (Supplementary 
Figures 3a and 3b) showed no significant differences between genotypes. However, when 
VEGFR2, phosphorylated VEGFR2, and the ratio of phosphorylated VEGFR2 to total 
VEGFR2 were quantified (Figure 2d), activation of VEGFR2 was once again reduced 
approximately 50% in mutant tumors relative to wild type tumors.
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We next wished to determine the relationship between expression of myeloid cell VEGF and 
vessel normalization; to assay this, we visualized pericyte coverage of tumor vessels, and 
assayed levels of vessel pericyte coverage in the tumors (Figure 2e). As shown, the loss of 
VEGF expression in the myeloid cells resulted in a marked increase in the level of vessel 
pericyte association, indicating that VEGF expression from infiltrating myeloid cells is 
essential for intratumoral loss of vessel pericyte coverage. Vessel permeability also 
decreased in tumors from mutant animals (Figure 2f).
Hypoxia is associated with solid tumor growth and with tumorigenic vasculature. We found 
that the more slowly growing wild type tumors had higher levels of hypoxia (Figure 3a and 
Supplementary Figure 3c); and that this occurred even in areas that were extensively 
vascularized (Supplementary Figure 3c). Interestingly, staining of tumor sections with 
VEGF and F4/80, a macrophage marker, demonstrates that intense VEGF immunostaining 
in wild type tumors occurs in regions of high infiltration, whereas in mutant tumors VEGF 
staining is only found outside of infiltrated regions (Supplementary Figure 3d); this depicts 
how VEGF from myeloid cells could have an acute and localized effect on tumor 
vasculature.
To determine whether the vascular changes we describe confer an increased susceptibility to 
cytotoxic agents, we administered the chemotherapy agent cyclophosphamide to wild type 
and mutant LLC tumor-bearing mice. Loss of myeloid-derived VEGF increased the 
chemotherapeutic efficacy of the treatment (Figures 3b,c). The cyclophosphamide treatment 
also resulted in a significantly increased level of tumor cell death in myeloid VEGF null 
tumor-bearing mice, as can be seen in Supplemental Figure 3e and as quantified in Figure 
3d. Similar experiments carried out with cis-platinum gave comparable results 
(Supplementary figures 3f and 3g).
To determine the differential contributions of tumor cell and myeloid cell-derived VEGF, 
we next created fibrosarcoma cell lines derived from C57Bl/6J embryos homozygous for the 
conditional allele of the VEGF gene. We then used cre recombinase expression from 
adenovirus to create matching wild type (infected with control adenovirus) and VEGF null 
(infected with cre recombinase-expressing adenovirus) tumor cell lines, and injected them 
subcutaneously into mice wild type or null for myeloid VEGF expression. As can be seen in 
Figure 4a, fibrosarcomas that were wild type for VEGF expression grew faster and 
significantly larger in mice lacking VEGF in myeloid cells, which is similar to what we 
observed in the other models described above. However, consistent with previous findings 
from our laboratory8, tumors lacking VEGF expression grew more slowly than those 
expressing VEGF when implanted into wild type mice (Figure 4a).
Interestingly, when VEGF was absent from both the tumor and the myeloid compartment, 
tumor growth essentially collapsed, with greatly increased apoptosis and necrosis (Figure 
4a-4f). Further, although there was a reduction in tumor vessel density (Figures 4b and 4d) 
ranging from the highest vessel count in tumors wild type in all tissue compartments, to the 
lowest in those lacking VEGF in tumor cells and myeloid cells, these values did not directly 
correspond to changes in tumor growth. Rather, they demonstrate the unique role for 
myeloid-derived VEGF in facilitating changes in tumor vessel function and normalization.
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Tumor-associated macrophages have been shown to be crucial for malignant progression in 
a mouse model of breast cancer7,9; however, these studies removed macrophages completely 
from tumors, and thus were removing all of the many aspects of macrophage involvement in 
tumor progression. In isolating one of those aspects experimentally, we have shown that 
myeloid-derived VEGF is required for the formation of a high-density vessel network, that 
loss of VEGF from this source greatly reduces activation of VEGFR2 in spite of little or no 
loss in total tumor VEGF, and that the absence of this increased vascular density does not 
hamper, but rather accelerates tumor progression.
When administered as single agents, anti-angiogenic drugs have produced modest objective 
responses in clinical trials, but overall, these single agent approaches have not yielded 
significant long-term survival benefits10. In contrast, when given in combination with 
chemotherapy, antibodies targeted against VEGF result in an increase in survival in 
colorectal cancer patients11. Our observations argue that a critical mediator of this 
sensitization to chemotherapy lies in the infiltrating innate immune cells, rather than in the 
malignant cells of the tumor. These findings open an important new avenue for the 
investigation of anti-angiogenic therapies targeted to tumor-associated cells of the immune 
system.
Methods Summary
Transgenic mice (C57Bl/6J) expressing the polyoma middle T (PyMT) oncoprotein under 
the promoter of the mouse mammary tumor virus (MMTV)-long terminal repeat were bred 
to mice (C57Bl/6J) with both alleles of exon 3 of VEGF-A flanked by loxP sites (VEGF
+f/+f)12. Myeloid cell-specific knock out of VEGF was achieved by breeding male mice 
homozygous for the floxed VEGF allele and hemizygous for the PyMT oncogene (MMTV-
PyMT/VEGF+f/+f) with female mice (C57Bl/6J) homozygous for the floxed VEGF allele 
expressing Cre recombinase driven by the lysozyme M promoter (LysMCre+/VEGF+f/+f)4. 
For our studies, we used female mice hemizygous for the PyMT oncogene carrying two 
floxed VEGF alleles and positive for cre-expression (MMTV-PyMT/LysMCre+/VEGF
+f/+f) designated as mutants (Mut) whereas female littermates negative for cre expression 
(MMTV-PyMT/LysMCre-/VEGF+f/+f) served as wildtype controls (WT). Loss of VEGF 
expression in myeloid cells had no effect on normal mammary development (Supplemental 
Figure 1c).
To generate isografts 1×107 Lewis lung carcinoma cells on a BL6 background (ATCC) were 
injected subcutaneously into LysMCre-/VEGF+f/+f (WT) and LysMCre+/VEGF+f/+f mice 
(Mut). Mouse embryonic fibroblasts (MEFs) were isolated from WT mice. The transgenic 
MEFs were immortalized by stable transfection with SV40 large T antigen and then 
transformed with a vector expressing oncogenic mutant H-Ras (Val-12). Subsequently, the 
VEGF+f/+f MEFs were infected with an adenovirus expressing Cre recombinase to delete 
exon 3 of the VEGF gene. A total of 5×106 of VEGF null or wildtype MEF's were injected 
subcutaneously into WT and Mut mice. Data are expressed as mean ± SEM. Statistical 
significance was determined by two-tailed unpaired t test.
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The treatment with chemotherapy was started six days post-injection of 1×107Lewis lung 
carcinoma cells. Cisplatin (5mg/kg) and Cyclophosphamide (170mg/kg) were purchased 
from Sigma and given i.p. every second day until day 10.
Histology, immunohistochemistry and immunofluorescence
For whole-mount preparation of mammary glands, the inguinal gland was removed and 
fixed in 10% phosphate-buffered formalin (Fisher Scientific, Fair Lawn, NJ) and dehydrated 
through a series of graded acetone and ethanol washes. Glands were stained for 3 h with 
Harris hematoxylin (VWR Int., West Chester, PA), and excess stain was removed by 
washing in water. Glands were destained in acidic 50% ethanol and dehydrated and stored in 
methyl salicylate (Fisher Scientific).
After removal tumors were fixed in 10% Formalin, Zinc fixative (BD Pharmingen) or 4% 
paraformaldehyde, respectively and then embedded in paraffin. For hematoxylin-eosin 
(H&E) and immunostaining, 5μm sections were deparaffinized with xylene and rehydrated 
with graded ethanol. The sections were stained according to routine immunohistochemistry 
procedures and visualized by Vectastain ABC or ABC-AP kit (Vector Laboratories, 
Burlingame, CA).
Primary antibodies used for immmunohistochemistry and immunofluorescence: biotinylated 
rat anti-CD 31 at 1:100 dilution (BD Pharmingen), rat anti-CD 34 (Novus), biotinylated 
mouse anti-PCNA at 1:800 dilution (BD Pharmingen), biotinylated rat anti-F4/80 at 1:200 
dilution (Serotec), rabbit anti-VEGF at 1:50 dilution (sc-152, Santa Cruz), mouse anti-SMA-
alpha at 1:500 (Chemicon). The fluorochrome-conjugated Alexa 488 and Alexa 555 were 
used as secondary antibodies (1:200).
Pimonidazole Hydrochloride (Hypoxyprobe™-1) was injected intraperitoneally (60 mg/kg 
bodyweight) 1 hour prior to tumor removal and was detected with a Mouse IgG1 
monoclonal antibody (Mab1, Natural Pharmacia International).
TUNEL-Assay (Promega) was performed according to the manufacturers instructions.
Quantitative analysis of histologic markers
For quantitative analysis of the distribution of immunohistochemical markers within the 
tumor, the midline sections of tumors were photographed into TIFF images using a Leica 
DMR microscope and SPOT™ RT color camera system (Diagnostic Instruments Inc.) and 
the area (number of pixels) with positive staining equal to or greater than a set threshhold 
was measured using the Image J program and such marked areas were normalized by the 
number of images for each tumor. For comparison at different stages of progression PyMT 
tumors were classified as previously described7.
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To determine vessel density, the vasculature marked by CD 31 and CD 34 was skeletonized 
using the Image J program and the area covered by blood vessels was measured and the 
number of vessels per field was determined, respectively.
To estimate change in vessel length, the skeletonized blood vessels that showed up in a 
longitudinal cut within an image were traced along their midline and the number of pixels 
was converted into distance in millimeters using Image J.
The tortuosity (T) of blood vessel was defined by the following equation:
T=L/S − 1
where L is the length of the vessel of interest and S the straight line distance between its 
endpoints.
Confocal microscopy
Co-localization of pericytes (SMA-α) endothelial cells (CD 31) was imaged on 20-μm 
sections of excised LLC tumors. Images were acquired using laser scanning confocal 
microscopy under 60/1.4 NA oil objective (Nikon C1si, Nikon Instruments Inc).
Flow cytometry
Tumors were excised and cut into small pieces before incubation in a shaker at 37 degrees at 
250 RPM for 2 hours in 0.1% Collagenase A (Roche) in RPMI 1640 (Invitrogen). The 
resulting single cell suspension was pelleted and rinsed in PBS before treatment with 
hypotonic lysis buffer and passing through a 40uM cell strainer (BD Biosciences). One 
million cells per condition were then incubated with Fc Block (BD Biosciences) to block 
nonspecific FcR binding before labeling with fluorescently conjugated antibodies 
(eBiosciences) using standard protocols. Data was acquired on a FACSCalibur flow 
cytometer (BD Biosciences) with propidium iodide to exclude non-viable cells and analyzed 
with FlowJo Software (Tree Star).
Determination of vascular permeability
200 μl of Fluorescein isothiocyanate-dextran (2,000,000 MW, Sigma) were injected 
intravenously at a concentration of 50mg/ml. After 10 minutes tumors were removed and 
immediately frozen in OCT compound. 10 μm cryosections were cut and vascular 
permeability was determined based on 10 randomly taken pictures from each tumor. By 
using Image J the edges of blood vessel were indentified and the extravascular as well as the 
intravascular area (number of pixels) covered by FITC-dextran were measured. In order to 
determine vascular permeability in a quantitative manner the amount of extravascular 
staining over the amount of intravascular FITC-dextran was calculated.
Immunoprecipitation and Immunoblotting
Tumors were lysed in RIPA buffer and 500 μg of lysate were used for immunoprecipitation 
of VEGFR2. The following antibodies were used in this study: rabbit anti-VEGFR2 (55B11, 
Cell signaling), HRP-conjugated anti-phosphotyrosine (4G10®, Millipore), rabbit anti-
VEGF (sc-152, Santa Cruz) and mouse anti-β-actin (Sigma). For a quantitative analysis the 
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membranes were scanned with a fluorescense scanner and the signal stength was determined 
by using ImageQuant® software.
Determination of deletion frequency and gene expression by quantitative PCR
Thioglycollate-elicited macrophages as well as FACS sorted F4/80-positive tumor-
associated macrophages isolated from PyMT-Mut tumors were used for isolation of genomic 
DNA as previuously described5. Whole tumors were ground to a fine powder in liquid 
nitrogen and subsequently homogenized in TRIzol® reagent (Invitrogen). Total RNA was 
isolated following the manufacturer's instructions. For real-time PCR analysis, the isolated 
RNA was reverse transcribed. For PCR reactions, TaqMan-Universal Mastermix (Applied 
Biosytems) was used. 50 ng cDNA was used as template to determine the relative amount of 
mRNA by real-time PCR (ABI Prism 7700 sequence detection system), using specific 








Cells were cultured in Dulbecco's modified Eagle's medium (DMEM High Glucose), 
supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, 50 U/ml penicillin and 
100μg/ml streptomycin.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Deletion of VEGF in myeloid cells results in reduced vascularization but accelerated 
progression of mammary tumors.
a, Total tumor mass of PyMT-WT mice (n=15) and PyMT-Mut mice (n=13) at the age of 20 
weeks. b, Distribution of PyMT mammary tumors at prototypical premalignant (PM) 
lesions, malignant early carcinoma (EC) and late carcinoma (LC) stages in percent (±s.e.m.) 
between genotypes and at the age of 16 (n=4) and 20 weeks (PyMT-WT n=4, PyMT-Mut 
n=9). c, Quantitative analysis of the area covered by CD 31-positive cells within a tumor 
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section for each stage (n=4). d, Development of vessel length in PyMT-tumors during 
malignant progression as determined by tracing CD 31-positive vessels that were exposed in 
a longitudinal cut (n=4). e, Analysis of vessel tortuosity based on CD 31-stained tumor 
sections (n=4). f, Quantitative analysis of the VEGF signal (PyMT-WT n=7, PyMT-Mut 
n=4). g, ratio of p-Tyr and VEGFR2 signal intensities as a measure of receptor activation 
(PyMT-WT n=7, PyMT-Mut n=4). Scale bars, 100 μm; **p<0.01, ***p<0.001; error bars, 
s.e.m.
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Deletion of VEGF in myeloid cells leads to a normalized vasculature and higher tumor 
volumes in Lewis Lung Carcinoma isografts.
a, Growth curve analysis of Lewis Lung Carcinoma (LLC) tumors injected subcutaneously 
in WT and Mut mice (n>7 for each group). b, Quantitative analysis of CD 31-positive 
endothelial cells (n=4). c, Determination of blood vessel tortuosity in LLC tumors. d, Left: 
Immunoblotting for VEGFR2 and phosphotyrosine (p-Tyr) after Immunoprecipitation of 
VEGFR2 from LLC tumor lysates. Center: Quantitative analysis of VEGFR2 (upper) and 
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phosphotyrosine (lower) signals. Right: Ratio of p-Tyr and VEGFR2 signal intensities as a 
measure of receptor activation (WT n=8, Mut n=7). e, Left: Confocal microscopy images of 
simultaneous immunodetection of endothelial cells and pericytes in LLC tumors with the 
specific markers CD 31 and smooth muscle actin-alpha (SMA-alpha). Right: Pericyte 
coverage as assessed by SMA-alpha/CD 31 co-localization (n=4). f, Left: Fluorescent 
microscopy images of a FITC-dextran angiography on LLC isografts. Right: Ratio of 
extravascular over intravascular FITC-dextran as a measure of vascular permeability (WT 
n=6, Mut n=4). Scale bar, 100 μm; error bars, s.e.m.
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Deletion of VEGF myeloid cells results in reduced hypoxia and increased susceptibility of 
LLC tumors to cytotoxic agents.
a, Quantitative analysis of hypoxic tumor areas (WT n=6, Mut n=4). b, Growth curve 
analysis of LLC isografts from WT and Mut animals (n>4 for each group) treated with 
Cyclophosphamide (CYCP) (170mg/kg) at day 6, 8 and 10 after tumor implantation. c, 
Response of tumors from WT and Mut mice to CYCP treatment expressed as percentage of 
treated tumor volume to untreated tumor volume at specified time points. d, Quantitative 
analysis of TUNEL positive on CYCP-treated LLC isografts (n=4). Scale bar, 100 μm; error 
bars, s.e.m.
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Effect of tumor cell-derived versus myeloid cell-derived VEGF on tumor angiogenesis and 
growth.
a, Growth curve analysis of wildtype (WT) and VEGF nullizygous (null) fibrosarcoma 
isografts (genotype labeled in black) implanted into WT-mice or Mut-mice (null) with a 
myeloid cell-specific deletion of VEGF (genotype labeled in blue) (n=4 for each group). b, 
CD 34 immunostaining on fibrosarcoma isografts. c, Detection of apoptotic cells in 
fibrosarcomas by TUNEL-staining. d, Quantitative analysis of CD 34-positive blood vessels 
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(n=4). e, Quantification of TUNEL-positive cells (n=4). f, Assessment of tumor necrosis on 
fibrosarcoma midline sections. Shown is the perimeter of necrotic areas expressed as 
percentage of total tumor perimeter (n=4). Scale bar, 100 μm; error bars, s.e.m.
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